NFKB1 and breast cancer: Namely, Tyagi et al. [108] recently reported that a follow-up treatment of SAL may be a promising strategy against cisplatin (cis-diamminedichloro-platinum, CDDP)-resistant breast cancer cells and metastasis and help reduce CDDP-induced side effects as it reduces the growth, proliferation, and metastasis of cisplatin-resistant breast cancer cells via NF-kB deregulation.